Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Director Adam K. Stern purchased 20,000 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were acquired at an average price of $0.80 per share, for a total transaction of $16,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NYSEAMERICAN:MTNB traded down $0.03 during trading on Friday, reaching $0.80. 561,282 shares of the stock were exchanged, compared to its average volume of 1,039,420. Matinas BioPharma Holdings Inc has a 1-year low of $0.32 and a 1-year high of $1.50.

Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its earnings results on Monday, May 13th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01).

MTNB has been the topic of a number of research reports. Zacks Investment Research raised Matinas BioPharma from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a research report on Tuesday, April 16th. BTIG Research initiated coverage on Matinas BioPharma in a research report on Friday, May 17th. They set a “buy” rating and a $5.00 target price on the stock. Finally, Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of Matinas BioPharma in a research report on Thursday, May 16th.

Several large investors have recently modified their holdings of the company. IPG Investment Advisors LLC raised its position in Matinas BioPharma by 54.5% in the 1st quarter. IPG Investment Advisors LLC now owns 42,500 shares of the company’s stock valued at $46,000 after buying an additional 15,000 shares during the last quarter. Private Advisor Group LLC raised its position in Matinas BioPharma by 100.4% in the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after buying an additional 24,978 shares during the last quarter. Jane Street Group LLC raised its position in Matinas BioPharma by 190.1% in the 1st quarter. Jane Street Group LLC now owns 41,452 shares of the company’s stock valued at $45,000 after buying an additional 27,165 shares during the last quarter. Northern Trust Corp raised its position in Matinas BioPharma by 18.9% in the 4th quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock valued at $109,000 after buying an additional 29,072 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Matinas BioPharma in the 1st quarter valued at $39,000.

ILLEGAL ACTIVITY WARNING: “Adam K. Stern Buys 20,000 Shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) Stock” was first published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/adam-k-stern-buys-20000-shares-of-matinas-biopharma-holdings-inc-nyseamericanmtnb-stock/3042669.html.

Matinas BioPharma Company Profile

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

See Also: How to invest in a bear market

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.